Complications of palliative antiangiogenic therapy in patients with colorectal cancer
Journal Title: OncoReview - Year 2016, Vol 6, Issue 4
Abstract
Introduction: Bevacizumab is an antiangiogenic drug used in the therapy of numerous solid tumours including colorectal adenocarcinoma. The efficacy and safety of bevacizumab has been demonstrated in many multicenter clinical trials. The scope of this paper is to analyze the safety profile of bevacizumab in patients with stage IV colorectal cancer.
Authors and Affiliations
Małgorzata Domagała-Haduch, Marek Jasiówka, Łukasz Nowak, Ida Cedrych
Keywords
Related Articles
- EP ID EP186912
- DOI 10.5604/01.3001.0009.5069
- Views 213
- Downloads 0
Papillary renal cell carcinoma – case report of a patient with disseminated disease treated with pazopanib with several years of survival against reviewing current literature
Papillary renal cell carcinoma is the second most common histological type of renal cell carcinoma with distinct cytogenetics, histology and prognosis. It exhibits significantly poorer response to molecular targeted ther...
Stwardnienie guzowate
Stwardnienie guzowate jest wieloukładowym schorzeniem genetycznym charakteryzującym się występowaniem rozsianych guzów hamartomatycznych w różnych narządach, w tym w mózgu, mięśniu sercowym, skórze, oczach, nerkach, płuc...
Role of molecular examinations in qualification to first line treatment with erlotinib in NSCLC patients based on EURTAC study results
Between 2010–2011 the first EGFR thyrosine kinase inhibitor (EGFR TKI) – gefitinib, was registered in many countries in I line of treatment in patients with advanced and locally advanced non-small cell lung cancer (NSCLC...
Targeted therapies for chronic myeloid leukemia and cardiovascular system
Morbidity of chronic myeloid leukemia is recorded in elderly population, in patients with coexisting significant risk factors for atherosclerosis and heart diseases. Molecularly targeted therapy, imatinib, dasatinib and...
Non-pegylated liposomal doxorubicin plus capecitabine as first-line treatment in metastatic breast cancer
Purpose: To determine the toxicity and efficacy profile of non-pegylated doxorubicin in combination with capecitabine administered according to LipAX regimen.